Literature DB >> 18983461

Immunophenotypic analysis of the Kaposi sarcoma herpesvirus (KSHV; HHV-8)-infected B cells in HIV+ multicentric Castleman disease (MCD).

A Chadburn1, E M Hyjek, W Tam, Y Liu, T Rengifo, E Cesarman, D M Knowles.   

Abstract

AIMS: Kaposi sarcoma herpesvirus (KSHV) is aetiologically related to Kaposi sarcoma, classical and extracavitary primary effusion lymphoma (PEL; EC-PEL) and multicentric Castleman disease (MCD), entities preferentially occurring in HIV-infected individuals. Characterization of HIV-associated PELs/EC-PELs suggests that the KSHV-infected malignant cells originate from a pre-terminal stage of B-cell differentiation. However, only limited phenotypic studies have been performed on HIV+ MCD, including for PR domain containing 1 with zinc finger domain/B lymphocyte-induced maturation protein 1 (PRDM1/BLIMP1), a key regulator of terminal B-cell differentiation. The aim was to characterize KSHV-infected cells in 17 cases of HIV+ MCD. METHODS AND
RESULTS: Double immunohistochemistry and immunohistochemistry-in situ hybridization were used to characterize the KSHV-infected cells in MCD; the results were compared with the phenotypic profiles of 39 PELs/EC-PELs and seven PEL cell lines. Whereas the immunophenotype of KSHV-infected cells in MCD and malignant KSHV+ PEL cells was similar (PAX5, Bcl-6-; PRDM1/BLIMP1, IRF4/MUM1+; Ki67+), the MCD KSHV-infected cells differed, as they expressed OCT2, cytoplasmic lambda immunoglobulin; variably expressed CD27; lacked CD138; and were Epstein-Barr virus negative.
CONCLUSIONS: Although both PEL and MCD originate from KSHV-infected pre-terminally differentiated B cells, these findings, with previously reported genetic studies, indicate HIV+ MCD may arise from extrafollicular B cells, whereas PELs may originate from cells that have traversed the germinal centre.

Entities:  

Mesh:

Year:  2008        PMID: 18983461     DOI: 10.1111/j.1365-2559.2008.03144.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  36 in total

Review 1.  Extrafollicular activities: perspectives on HIV infection, germinal center-independent maturation pathways, and KSHV-mediated lymphoproliferation.

Authors:  Jennifer Totonchy
Journal:  Curr Opin Virol       Date:  2017-08-03       Impact factor: 7.090

2.  Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.

Authors:  Mark N Polizzotto; Thomas S Uldrick; Victoria Wang; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Stefania Pittaluga; Deirdre O'Mahony; Denise Whitby; Giovanna Tosato; Seth M Steinberg; Richard F Little; Robert Yarchoan
Journal:  Blood       Date:  2013-10-30       Impact factor: 22.113

3.  High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy.

Authors:  Thomas S Uldrick; Mark N Polizzotto; Karen Aleman; Deirdre O'Mahony; Kathleen M Wyvill; Victoria Wang; Vickie Marshall; Stefania Pittaluga; Seth M Steinberg; Giovanna Tosato; Denise Whitby; Richard F Little; Robert Yarchoan
Journal:  Blood       Date:  2011-04-12       Impact factor: 22.113

Review 4.  Multicentric Castleman disease: Where are we now?

Authors:  Hao-Wei Wang; Stefania Pittaluga; Elaine S Jaffe
Journal:  Semin Diagn Pathol       Date:  2016-05-16       Impact factor: 3.464

Review 5.  Viral interleukin-6: role in Kaposi's sarcoma-associated herpesvirus: associated malignancies.

Authors:  Shuhei Sakakibara; Giovanna Tosato
Journal:  J Interferon Cytokine Res       Date:  2011-07-18       Impact factor: 2.607

6.  Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease.

Authors:  Thomas S Uldrick; Mark N Polizzotto; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Denise Whitby; Victoria Wang; Stefania Pittaluga; Deirdre O'Mahony; Seth M Steinberg; Richard F Little; Robert Yarchoan
Journal:  Blood       Date:  2014-10-20       Impact factor: 22.113

7.  New developments in the pathology of malignant lymphoma: a review of the literature published from August to December 2008.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-03       Impact factor: 0.196

8.  Vironome of Kaposi sarcoma associated herpesvirus-inflammatory cytokine syndrome in an AIDS patient reveals co-infection of human herpesvirus 8 and human herpesvirus 6A.

Authors:  Kristen M Tamburro; Dongmei Yang; Jessica Poisson; Yuri Fedoriw; Debasmita Roy; Amy Lucas; Sang-Hoon Sin; Nadia Malouf; Vincent Moylan; Blossom Damania; Stephan Moll; Charles van der Horst; Dirk P Dittmer
Journal:  Virology       Date:  2012-08-24       Impact factor: 3.616

9.  The product of Kaposi's sarcoma-associated herpesvirus immediate early gene K4.2 regulates immunoglobulin secretion and calcium homeostasis by interacting with and inhibiting pERP1.

Authors:  Lai-Yee Wong; Kevin Brulois; Zsolt Toth; Kyung-Soo Inn; Sun-Hwa Lee; Kathryn O'Brien; Hyera Lee; Shou-Jiang Gao; Ethel Cesarman; Armin Ensser; Jae U Jung
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

Review 10.  Kaposi sarcoma associated herpesvirus pathogenesis (KSHV)--an update.

Authors:  Dirk P Dittmer; Blossom Damania
Journal:  Curr Opin Virol       Date:  2013-06-13       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.